Register / Log In

Dr. Tewari named urology chair at Mount Sinai


Ashutosh K. Tewari, MB, BS, has been named chairman of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai, New York, effective Oct. 15, 2013.

“Dr. Tewari is a top-flight urologist and physician scientist of national and international repute who will position Mount Sinai as a urologic center of excellence, offering world-class urologic care, practice-changing research, and patient-centered care,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and president of academic affairs for the Mount Sinai Health System. “Dr. Tewari is known for his work in developing the fields of robotic prostatectomy, and outcomes research using novel medical imaging and genomics research.”

Dr. Tewari comes to the Icahn School of Medicine at Mount Sinai after serving as director of the Lefrak Center for Robotic Surgery at New York-Presbyterian Hospital/Weill Cornell Medical Center, New York. Last year, he received the AUA’s Gold Cystoscope Award for his outstanding contributions to the field of urology and urologic oncology.

Dr. Tewari pioneered robotic prostatectomy, and he has performed more than 5,000 robotic prostatectomies and other minimally invasive procedures for various urologic cancers. He has managed a robust urologic training program at New York Presbyterian Hospital/Weill Cornell Medical Center since 2004. Dr. Tewari has trained more than 30 fellows and residents in robotics and has made presentations on innovation in robotics at major medical meetings in the U.S. and internationally.

Dr. Tewari is actively pursuing studies of the radiologic phenotype of aggressive prostate cancer using novel imaging and genomics.

“My vision for the department of urology is to create a highly engaged team committed to world-class care, strong faculty and trainee development, and innovative research and discovery,” said Dr. Tewari.

Dr. Tewari was awarded his medical degree from the GSVM Medical College in Kanpur, India, where he received 18 gold medals and honors. He obtained specialized urologic training at the Sanjay Gandhi Post Graduate Institute in Lucknow, India; residency training at the Vattikuti Institute of Urology at Henry Ford Hospital in Detroit; as well as fellowships in urologic oncology at the University of California, San Francisco and the University of Florida at Gainesville.


To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
 

Data from a phase II study suggest that the potency of sipuleucel-T (Provenge) and immunologic prime-boost responses are maintained when the immunotherapy is administered concurrently or sequentially with abiraterone acetate (ZYTIGA) plus prednisone.

The University of Michigan Health System said it has begun offering a new urine test for prostate cancer that incorporates three specific markers for the disease, and studies have shown that the combination is significantly more accurate than the PSA test alone.

In the latest examination of population-based screening for prostate cancer, French researchers say PSA testing does more harm than good.